This year, one of the National Therapeutic Indicators (NTI) asks practices to review their spend on gabapentin and pregabalin. Gabapentin is less costly if multiple lower strength capsules are taken in preference to the higher strength options. Conversely pregabalin is less costly if higher strength capsules are taken in preference to multiples of lower strengths.
This review will only look at converting patients to a more cost-effective dosing regime of their current drug.